Generic drug manufacturers Lupin and Gavis Pharmaceuticals have agreed to sell the rights and assets for two generic drugs, in order to address regulatory concerns over their merger.

The US Federal Trade Commission (FTC) has asked the companies to divest the products as it is concerned that the proposed $850m acquisition would reduce competition in the market.

FTC said: "Without a divestiture, the merger would have combined two of only four companies that currently market generic doxycycline monohydrate capsules in two dosage strengths, used to treat bacterial infections, likely resulting in higher prices."

The companies have decided to sell generic drugs for treating bacterial infections and ulcerative colitis to G&W Laboratories.

"The companies have decided to sell generic drugs for treating bacterial infections and ulcerative colitis to G&W Laboratories."

Lupin would transfer all of Gavis’ rights and assets related to generic doxycycline monohydrate capsules to G&W Laboratories within ten days after the acquisition is consummated, so that G&W can begin selling the product immediately.

The transfer includes Gavis’ manufacturing technology, which Lupin will help G&W set up at the latter’s facilities. In the interim, Lupin will supply G&W with the finished product for two years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lupin is also required to transfer all confidential business data related to both divested products, and provide access to knowledgeable employees, so that G&W can obtain all necessary FDA approvals in a timely manner.

Meanwhile, Gavis will divest its rights and assets related to generic mesalamine capsules to G&W before the acquisition takes place.

If the deal goes ahead, Lupin will expand its presence in the US generic market, in addition to its portfolio in dermatology, controlled substance products and other niche generics.

Based in New Jersey, Gavis is involved in formulation development, manufacturing, packaging, sales, marketing, and distribution of pharmaceuticals products.

Currently, the firm has 66 ANDA filings pending approval with the US FDA, as well as pipeline of around 65 niche dosage forms. The company has also filed 25 Para IVs and eight FTFs products.